BioSpace News Archive

The Rockefeller University announced that Paula Volent has been named vice president and chief investment officer of the University.

Clearsense, an advanced data management and analytics technology platform serving the healthcare industry, announced today it has closed $30 million in financing in partnership led by Health Catalyst Capital.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

SHINE Medical Technologies LLC today announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building is weathertight, a major milestone with significance for SHINE, the medical isotope industry and patients around the world.

– LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling patients – – IND submissions planned for Parkinson’s disease dementia program in 1H 2021 and neuropsychiatric program by end of 2021 –

- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today, March 25, 2021 at 1:30 p.m. Pacific / 4:30 p.m. Eastern -

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies, announced today the presentation of new clinical data on LHF-535 at the International Conference on Antiviral Research

Muno-Vax’s supplement Respistim is designed to support the immune system, especially during the cold, sickness-prone winter months.

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies, today announced that it has received the TRIP (TRG Rapid Inquiry Program) response from the FDA’s Tissue Reference Group (TRG) for the Company’s amniotic membrane allograft, VENDAJE™

SOPHiA GENETICS SA (“SOPHiA GENETICS”), pioneer in Data-Driven Medicine, and Hitachi, Ltd. (TSE: 6501, “Hitachi”) today announced they have entered into a long-term collaboration agreement to bring clinical, genomic and real-world insights to healthcare providers